We are live on ! Find out more
LAB icon

Standard BioTools

0.6900 USD
+0.0003
0.04%
At close Updated Sep 11, 4:00 PM EDT
1 day
0.04%
5 days
2.09%
1 month
-12.38%
3 months
-23.92%
6 months
-29.11%
Year to date
-45.67%
1 year
-48.12%
5 years
-89.96%
10 years
-91.54%
 

About: Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.

Employees: 389

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 100%
Negative 0%
Neutral
GlobeNewsWire
1 month ago
Standard BioTools Reports Second Quarter 2026 Financial Results
BOSTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended June 30, 2026.
Standard BioTools Reports Second Quarter 2026 Financial Results
Neutral
GlobeNewsWire
1 month ago
Standard BioTools Announces Sale of Mass Cytometry Business and Illumina's Buyout of Contingent Payments to Advance Merger with Treeline Biosciences
Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms
Standard BioTools Announces Sale of Mass Cytometry Business and Illumina's Buyout of Contingent Payments to Advance Merger with Treeline Biosciences
Neutral
GlobeNewsWire
1 month ago
Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026
BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its second quarter 2026 financial results on Wednesday, August 5, 2026, after U.S. market close. About Standard BioTools Inc.
Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026
Neutral
GlobeNewsWire
1 month ago
Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction
Highlights combined company's strong financial position with over $900 million expected at closing, Treeline's deep clinical-stage pipeline, planned 2027 data updates for TLN-121 and TLN-372, and expected new program clinical starts
Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction
Neutral
Business Wire
2 months ago
LiveRamp Launches Agentic Partner Program to Fast-Track Agentic Deployments for Customers
SAN FRANCISCO--(BUSINESS WIRE)--LiveRamp (NYSE: RAMP), the leader in data collaboration, today announced LiveRamp Agent Builders (LAB), a new program to bring more partner-built agents into its network and accelerate marketers' ability to transform planning, measurement, activation, and data transformation with AI. During LAB's pilot period, brands will have access to agents from all of the AI companies participating in the program, enabling customers to focus on finding tools that create value.
LiveRamp Launches Agentic Partner Program to Fast-Track Agentic Deployments for Customers
Neutral
Business Wire
2 months ago
LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Standard BioTools Inc. (NASDAQ: LAB) and Treeline Biosciences, Inc. Upon closing of the proposed transaction, Standard BioTools shareholders are expected to own approximately 16% of the combined company. Halper Sadeh encourages Standard BioTools shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 o.
LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders
Neutral
Newsfile Corp
3 months ago
Labrador Gold Announces 2026 Exploration Plans for Pacific Ridge's White Gold Projects
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2026) - Pacific Ridge Exploration Ltd. (TSXV: PEX) (OTCQB: PEXZF) (FSE: PQW) ("Pacific Ridge" or the "Company") is pleased to report that Labrador Gold Corp. (TSXV: LAB) ("LabGold") has announced plans for its 2026 exploration programs for the Company's Mariposa and Eureka Dome gold projects in the White Gold District, Yukon.
Labrador Gold Announces 2026 Exploration Plans for Pacific Ridge's White Gold Projects
Neutral
GlobeNewsWire
3 months ago
Labrador Gold to Host Investor Webinar on the Mariposa Gold Project in Yukon's White Gold District
TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX Venture: LAB) ("Labrador Gold" or the "Company") is pleased to announce that it will host a live investor webinar on Wednesday, June 17, 2026, at 12:00 PM PT / 3:00 PM ET, featuring President and CEO Roger Moss and moderated by Cory Fleck of the KE Report. The webinar will provide investors with an in-depth overview of the Company's recently acquired Mariposa Gold Project, including its strategic location within the Yukon's prolific White Gold District, historical exploration results, the recently approved Class 1 permit, planned 2026 exploration activities and upcoming catalysts as the Company advances this district-scale gold opportunity.
Labrador Gold to Host Investor Webinar on the Mariposa Gold Project in Yukon's White Gold District
Neutral
Seeking Alpha
3 months ago
Standard BioTools Inc. (LAB) Discusses Merger and Strategic Rationale Prepared Remarks Transcript
Standard BioTools Inc. (LAB) Discusses Merger and Strategic Rationale Prepared Remarks Transcript
Standard BioTools Inc. (LAB) Discusses Merger and Strategic Rationale Prepared Remarks Transcript
Neutral
GlobeNewsWire
3 months ago
Standard BioTools and Treeline Biosciences Announce Merger Agreement
Combined company to operate as Treeline Biosciences, advancing a deep pipeline of small molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates
Standard BioTools and Treeline Biosciences Announce Merger Agreement
Price charts implemented using Lightweight Charts™